27780748|t|Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer
27780748|a|Fatigue is the most common toxicity of all grade toxicities with regorafenib, was the second most common toxicity in the CORRECT (regorafenib monotherapy for previously treated metastatic colorectal cancer) study, and is a major reason for early dose modification. The results from a recent randomized study suggested that dexamethasone (DEX) can improve cancer-related fatigue. We retrospectively analyzed the effect of prophylactic use of an oral DEX on fatigue during regorafenib treatment in patients with metastatic colorectal cancer (mCRC). A total of 105 patients who had received regorafenib at our institution from May 2013 to August 2014 were divided into 2 groups according to oral DEX use (2 mg/day; at the physician's discretion). Of the 105 patients, 31 received prophylactic DEX and 74 received regorafenib alone. The time to dose modification was significantly longer in the DEX group than in the no DEX group (15 days vs. 9 days; P = .009). The incidence of fatigue (grade ≥ 1) was significantly lower with DEX than without DEX (25.8% vs. 50.0%; P = .022). Fewer patients experienced a decreased appetite (grade ≥ 1; 3.2% vs. 35.1%; P < .001) and hand-foot skin reaction (HFSR; grade ≥ 3; 3.2% vs. 25.7%, P = .002) with DEX than without DEX. DEX was effective in reducing fatigue during regorafenib treatment, resulting in prolonging the time to dose modification for regorafenib. The decreased incidence of appetite loss and HFSR also suggest that concurrent DEX administration with regorafenib warrants further investigation.
27780748	0	12	Prophylactic	T169	C0445202
27780748	20	38	Oral Dexamethasone	T200	C0360528
27780748	42	51	Alleviate	T061	C1274136
27780748	52	59	Fatigue	T184	C0015672
27780748	60	66	During	T079	C0347984
27780748	67	78	Regorafenib	T109,T121	C2980094
27780748	79	88	Treatment	T169	C0039798
27780748	93	101	Patients	T101	C0030705
27780748	107	135	Metastatic Colorectal Cancer	T191	C0948380
27780748	136	143	Fatigue	T184	C0015672
27780748	156	162	common	T081	C0205214
27780748	163	171	toxicity	T037	C0600688
27780748	179	184	grade	T185	C0441800
27780748	185	195	toxicities	T037	C0600688
27780748	201	212	regorafenib	T109,T121	C2980094
27780748	234	240	common	T081	C0205214
27780748	241	249	toxicity	T037	C0600688
27780748	257	264	CORRECT	T170	C0282574
27780748	266	348	regorafenib monotherapy for previously treated metastatic colorectal cancer) study	T170	C0282574
27780748	359	364	major	T080	C0205164
27780748	365	371	reason	T078	C0392360
27780748	376	381	early	T079	C1279919
27780748	382	399	dose modification	T062	C1707811
27780748	427	443	randomized study	T062	C2986910
27780748	459	472	dexamethasone	T109,T121	C0011777
27780748	474	477	DEX	T109,T121	C0011777
27780748	483	490	improve	T033	C0184511
27780748	491	513	cancer-related fatigue	T033	C4274302
27780748	518	542	retrospectively analyzed	T062	C0035363
27780748	547	553	effect	T080	C1280500
27780748	557	569	prophylactic	T169	C0445202
27780748	580	588	oral DEX	T200	C0360528
27780748	592	599	fatigue	T184	C0015672
27780748	607	618	regorafenib	T109,T121	C2980094
27780748	619	628	treatment	T169	C0039798
27780748	632	640	patients	T101	C0030705
27780748	646	674	metastatic colorectal cancer	T191	C0948380
27780748	676	680	mCRC	T191	C0948380
27780748	698	706	patients	T101	C0030705
27780748	724	735	regorafenib	T109,T121	C2980094
27780748	743	754	institution	T093	C2607850
27780748	789	796	divided	T169	C0332849
27780748	804	810	groups	T078	C0441833
27780748	824	832	oral DEX	T200	C0360528
27780748	855	866	physician's	T097	C0031831
27780748	891	899	patients	T101	C0030705
27780748	904	912	received	T080	C1514756
27780748	913	925	prophylactic	T169	C0445202
27780748	926	929	DEX	T109,T121	C0011777
27780748	946	957	regorafenib	T109,T121	C2980094
27780748	958	963	alone	T081	C0205171
27780748	977	994	dose modification	T062	C1707811
27780748	1027	1030	DEX	T109,T121	C0011777
27780748	1031	1036	group	T078	C0441833
27780748	1052	1055	DEX	T109,T121	C0011777
27780748	1098	1107	incidence	T081	C0021149
27780748	1111	1118	fatigue	T184	C0015672
27780748	1160	1163	DEX	T109,T121	C0011777
27780748	1169	1176	without	T080	C0332288
27780748	1177	1180	DEX	T109,T121	C0011777
27780748	1216	1224	patients	T101	C0030705
27780748	1225	1236	experienced	T041	C0596545
27780748	1239	1257	decreased appetite	T033	C0232462
27780748	1259	1264	grade	T185	C0441800
27780748	1300	1323	hand-foot skin reaction	T046	C2721716
27780748	1325	1329	HFSR	T046	C2721716
27780748	1331	1336	grade	T185	C0441800
27780748	1373	1376	DEX	T109,T121	C0011777
27780748	1382	1389	without	T080	C0332288
27780748	1390	1393	DEX	T109,T121	C0011777
27780748	1395	1398	DEX	T109,T121	C0011777
27780748	1403	1412	effective	T080	C1704419
27780748	1416	1424	reducing	T080	C0392756
27780748	1425	1432	fatigue	T184	C0015672
27780748	1440	1451	regorafenib	T109,T121	C2980094
27780748	1452	1461	treatment	T169	C0039798
27780748	1476	1486	prolonging	T079	C0439590
27780748	1491	1495	time	T079	C0040223
27780748	1499	1516	dose modification	T062	C1707811
27780748	1521	1532	regorafenib	T109,T121	C2980094
27780748	1538	1547	decreased	T081	C0205216
27780748	1548	1557	incidence	T081	C0021149
27780748	1561	1574	appetite loss	T033	C1971624
27780748	1579	1583	HFSR	T046	C2721716
27780748	1589	1596	suggest	T078	C1705535
27780748	1602	1612	concurrent	T079	C0205420
27780748	1613	1616	DEX	T109,T121	C0011777
27780748	1617	1631	administration	T061	C1533734
27780748	1637	1648	regorafenib	T109,T121	C2980094
27780748	1666	1679	investigation	T058	C0220825